



Demographics and socioeconomic

Total Population (in 1000) (2019)	389.49
Population <1 year of age (in 1000) (2019)	5.79
Population 1 year of age (in 1000)(2019)	5.47
Population <5 years of age (in 1000) (2019)	26.66
Women of childbearing age (2019)	209.61
Infant Mortality Rate (per 1000 live births) (2016)	16.00
Gross national income (US\$ per capita) current value (2017)	30,210.00
National Health Expenditure Public (2016)	3.18
National Health Expenditure Private (2016)	3.17

Immunization system highlights

- There is no comprehensive multi-year plan (MYP) for immunization.
- A standing national technical advisory group on immunization (NITAG) with formal written terms of reference exists. The group met 3 times in 2019.
- 99% of spending on routine immunization is financed using government funds.
- 100% of spending on vaccine purchases is financed using government funds.
- A national nominal electronic immunization registry implementation is in progress.


Immunization Schedule

BHS	Doses					
	1	2	3	4	5	6
BCG						
HepB_Pediatric	1ST CONTACT	1M	5M			
DTP-Hib				15MOS		
DTP-Hib-HepB	2M	4M	6M			
DTP-Hib-IPV						
DTP-Hib-HepB-IPV	2M	4M	6M			
DTP					4-5YRS	
IPV	2M	4M				
OPV			6MOS	4-5YRS		
MMR	1YR	15M				
Pneumoco_conj	2M	4M	6M	15M		
Rotavirus	2M	4M				
Td					EVERY 10 YRS	
TdaP					10-12 YRS	
HPV	1ST CONTACT	1-2M	6M			

Vaccine Introduction

	Year
Bacterial Meningitis	
<i>Haemophilus influenzae</i> type b	1998
Hepatitis B	2001
HPV	2015
Influenza	2005
MMR1	1991
MMR2	2001
Pentavalent	2001
Pneumococcal Conjugate	2012
Rotavirus	2014
Tdap	
Tetavalent DPT-Hib or DPT-HepB	
Yellow Fever	

Vaccination Coverage



Surveillance Indicators - AFP (CARPHA)

2019

Number of AFP suspected cases	8
AFP rate per 100,000 population <15 years old	0.57
% of cases with 1 adequate samples	100
% of cases investigated within <48 hours	100
% sites reporting	83


Surveillance Indicators - MR (CARPHA)

2019


Number of suspected cases	371
% of cases with adequate investigation	86
% of cases with adequate blood samples	98
% of samples received in laboratory <=5 days	9
% of laboratory samples results <=4 days	83




Polio3 coverage and AFP rate per 100,000 children <15 years of age




DTP3 coverage and number of reported diphtheria and pertussis cases




Number of tetanus (no neonatal) and neonatal tetanus cases



Proportion of municipalities by coverage range with DTP3 in children <1 years of age



DTP1-DTP3 and DTP1-MMR1 Dropout Rate



Legend

NB/nb-newborn
M/m-month
Y/y-year
WCBA-women of childbearing age

● with stockout
● no stockout
● no data available

Vaccine Stockout

BHS	2013	2014	2015	2016	2017	2018	2019
AD Syringes	●		●	●	●	●	●
BCG							
Disposable Syringes	●		●	●	●	●	●
DTP	●		●	●	●	●	●
HepB	●	●	●	●	●	●	●
Hib	●		●	●	●		
Influenza	●		●	●	●	●	●
IPV			●	●	●	●	●
Measles	●		●	●	●	●	●
Pneumo. Conjugate	●		●	●	●	●	●
Polio	●		●	●	●	●	●
Reconst. Syringes			●	●	●	●	
Rotavirus				●	●	●	●
Safety boxes	●		●	●	●	●	●
Tdap			●		●	●	●
TT	●		●	●	●	●	●
Yellow Fever	●		●	●	●	●	●